Lilly releases new exploratory data from TOGETHER-PsO Phase 3b trial
The company announced exploratory biomarker data from the TOGETHER-PsO Phase 3b study showing broader immune and metabolic changes when Taltz (ixekizumab) and Zepbound (tirzepatide) were used together versus Taltz alone. The analysis reported 482 versus 140 differentially expressed proteins and 467 versus 16 genes at Week 36, with greater reductions in inflammatory immune activity.
Primary source
Company press release (PR Newswire), October 9, 2026
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
Machine-summarized from the source above; not independently reported. How we use automation